Biodegradable Microsphere-Loaded Tacrolimus Enhanced the Effect on Mice Islet Allograft and Reduced the Adverse Effect on Insulin Secretion

American Journal of Transplantation

Volumn 4, Issue 5, 2004, Pages 721-727

  Wang, Quanxing ^a   Uno, Takeji ^b   Miyamoto, Yasunori ^c   Hara, Yuko ^a   Kitazawa, Yusuke ^a   Lu, Fei Zhou ^a   Funeshima, Naoko ^a   Fujino, Masayuki ^a   Yamamoto, Hiromitsu ^d   Takenaka, Hirofumi ^d   Kawashima, Yoshiaki ^d   Li, Xiao Kang ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Allogeneic islet transplantation; Biodegradable microsphere; Insulin; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INSULIN; MICROSPHERE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; FEMALE; GRAFT SURVIVAL; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; FEMALE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICROSPHERES; TACROLIMUS; TIME FACTORS;

EID: 2442424452     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00423.x     Document Type: Article

References (43)

1. Klintmalm GB. FK 506: an update. Clin Transplant 1994; 8: 207-210.
2. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256-1265.
3. Mouzaki A, Rungger D. Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. Blood 1994; 84: 2612-2621.
4. Shaw KT, Ho AM, Raghavan A et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A 1995; 92: 11205-11209.
5. Warty V, Diven W, Cadoff E, Todo S, Starzl T, Sanghvi A. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation 1988; 46: 453-455.
6. Fung JJ, Eliasziw M, Todo S et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117-125.
7. Jordan ML, Naraghi R, Shapiro R et al. Tacrolimus rescue therapy for renal allograft rejection-five-year experience. Transplantation 1997; 63: 223-228.
8. Pham SM, Kormos RL, Hattler BG et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-772.
9. Shapiro R, Scantlebury VP, Jordan ML et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62: 1752-1758.
10. Witzigmann H, Rhein T, Geissler F et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. Transplant Proc 2002; 34: 3354-3356.
11. Tan M, Cantarovich M, Mangel R, Paraskevas S, Fortier M, Metrakos P. Reduced dose Thymoglobulin (R), tacrolimus, and mofetil mycophenolate results in excellent solitary pancreas transplantation outcomes. Clin Transplant 2002; 16: 414-418.
12. Fay JW, Wingard JR, Antin JH et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87: 3514-3519.
13. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170-178.
14. Taler SJ, Textor SC, Canzanello VJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-1592.
15. Ayres RC, Dousset B, Wixon S, Buckels JA, McMaster P, Mayer AD. Peripheral neurotoxicity with tacrolimus. Lancet 1994; 343: 862-863.
16. Mach-Pascual S, Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996; 52: 310-312.
17. Shapiro AM, Geng HE, LakeyJR, Finegood DT, Rajotte RV, Kneteman NM. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. Transplantation 2002; 74: 1522-1528.
18. Dette K, Woeste G, Schwarz R, Wullstein C, Bechstein WO. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome. Transplant Proc 2002; 34: 1909-1910.
19. Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002; 74: 1568-1573.
20. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002; 16: 60-68.
21. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
22. Yang H, McAlister VC, Al Jazaeri A, Wright JR. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. Transplantation 2002; 73: 710-713.
23. Yura H, Yoshimura N, Hamashima T et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. J Control Release 1999; 57: 87-99.
24. Moffatt SD, McAlister V, Calne RY, Metcalfe SM. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Transplantation 1999; 67: 1205-1208.
25. Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10: 64-66.
26. Moxey-Mims MM, Kay C, Light JA, Kher KK. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998; 65: 617-619.
27. Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991; 23: 2748-2749.
28. Uno T, Yamaguchi T, Li XK et al. The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation. Lipids 1997; 32: 543-548.
29. Napoli R, Davalli AM, Hirshman MF, Weitgasser R, Weir GC, Horton ES. Islet transplantation under the kidney capsule fully corrects the impaired skeletal muscle glucose transport system of streptozocin diabetic rats. J Clin Invest 1996; 97: 1389-1397.
30. Filler G, Neuschulz I, Vollmer I, Amendt P, Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15: 867-871.
31. Cleland JL. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines. Biotechnol Prog 1998; 14: 102-107.
32. Yang Q, Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm 2000; 26: 61-70.
33. Molpeceres J, Aberturas MR, Guzman M. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. J Microencapsul 2000; 17: 599-614.
34. Urata T, Arimori K, Nakano H. Modification of release rates of cyclosporin A from polyl (1-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J Control Release 1999; 58: 133-141.
35. Wallemacq PE, Furlan V, Moller A et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998; 23: 367-370.
36. Hill CM, Douglas JF, Rajkumar KV, McEvoy J, McGeown MG. Glycosuria and hyperglycaemia after kidney transplantation. Lancet 1974; 2: 490-492.
37. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983; 6: 23-25.
38. Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996; 61: 1475-1478.
39. Sumrani N, Delaney V, Ding Z et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991; 23: 1249-1250.
40. Tze WJ, Tai J, Murase N, Tzakis A, Starzl TE. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 1991; 23: 3158-3160.
41. Ost L. Effects of cyclosporin on prednisolone metabolism. Lancet 1984; 1: 451.
42. Gillison SL, Bartlett ST, Curry DL. Inhibition by cyclosporine of insulin secretion-a beta cell-specific alteration of islet tissue function. Transplantation 1991; 52: 890-895.
43. Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995; 59: 1606-1613.